---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-187318"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2023-07-14T23:59:59+00:00"
generated_at: "2026-06-13T08:15:08.605348+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Frequency Therapeutics to merge with Korro Bio in reverse merger; Korro valued at ~$325.6M

## Summary
- Korro Bio equity valued at ~$325.6M; Frequency equity based on net cash at closing.
- Concurrent PIPE financing of ~$117M from accredited investors.
- Combined company board: 4 from Korro, 1 from Frequency, 2 independent.
- ~98% of Korro stockholders and ~11.7% of Frequency stockholders support merger.
- Frequency stockholders to receive CVRs for potential proceeds from MS asset sale.

## SEC filing metadata
- accession: 0001193125-23-187318
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2023-07-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312523187318/0001193125-23-187318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312523187318/d651936d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-187318
- JSON: https://secwatch.observer/filing/0001193125-23-187318.json
- Plain text: https://secwatch.observer/filing/0001193125-23-187318.txt

## Key facts
- Material Agreements
  Korro Bio, Inc. entered into Agreement and Plan of Merger with Frequency Therapeutics, Inc., Frequency Merger Sub, Inc. valued at approximately $325.6 million (effective 2023-07-14).
  - Action: entry
  - Agreement: merger
  - Counterparty: Frequency Therapeutics, Inc., Frequency Merger Sub, Inc.
  - Value: approximately $325.6 million
  - Effective: 2023-07-14
  source text: On July 14, 2023, Frequency Therapeutics, Inc. (“ Frequency ” or the “ Company ”), Frequency Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ Merger Sub ”), and Korro Bio, Inc., a Delaware corporation (“ Korro Bio ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000119312523187318/0001193125-23-187318-index.htm
- Material Agreements
  Korro Bio, Inc. entered into Subscription Agreements with certain accredited investors valued at approximately $117 million (effective 2023-07-14).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $117 million
  - Effective: 2023-07-14
  source text: On July 14, 2023, Korro Bio entered into subscription agreements with certain accredited investors for the Concurrent Financing with expected gross proceeds to Korro Bio of approximately $117 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000119312523187318/0001193125-23-187318-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.